1. Medtech Insight
  2. >>Archive

Genomics and Proteomics Forays into Psychiatric Illness

The first genome-wide association study for genetic variations linked to bipolar disorder illustrates both the opportunities and the challenges of developing genomic and proteomic tests that can inform drug development and treatment of poorly understood psychiatric diseases.

Mark L. Ratner

There’s been an upswing in interest in diagnostics by some of the more influential VCs and once again it’s triggering talk of whether—and in what areas—genomics- or proteomics-based tests could form the basis for a sustainable business. (See "Pharma Venturing in Diagnostics," sidebar in "Wake-up Calls in IVD," IN VIVO, April 2007 Also see "Wake-up Calls in IVD" - In Vivo, 1 April, 2007.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 
• By Amanda Maxwell

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

Will NICE’s New Medtech Evaluation Plans Hit the Target for Patients and Industry?

 
• By Ashley Yeo

One year after the UK mooted the Rules-Based Pathway to give medtechs clarity on what can be expected from an evaluation, the devices industry says UK healthtech assessment and adoption processes are still failing to meet the needs of innovators and patients.

The Value Of Consumer Wearables Within The Clinic Is Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”